Cytokinetics financials
$65.64−0.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28.6M | $19.4M | $17.8M | $1.9M | $66.8M | $1.6M | $16.9M | $463.0K | $249.0K | $835.0K | $1.7M | $378.0K |
| Gross profit | $25.9M | $16.8M | $17.8M | $1.9M | $66.8M | $0.00 | $16.9M | $463.0K | $249.0K | $835.0K | $1.7M | $378.0K |
| Gross margin | 90.5% | 86.8% | 100.0% | 100.0% | 100.0% | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$179.2M | -$183.6M | -$178.4M | -$166.8M | -$111.5M | -$155.6M | -$139.0M | -$140.8M | -$130.2M | -$126.2M | -$127.4M | -$122.3M |
| Net income | -$198.8M | -$206.0M | -$183.0M | -$306.2M | -$134.4M | -$161.4M | -$150.0M | -$160.5M | -$143.3M | -$135.6M | -$136.9M | -$129.4M |
| Net margin | −694.4% | −1064.5% | −1030.9% | −15815.0% | −201.2% | −10220.1% | −886.3% | −34674.9% | −57557.4% | −16244.7% | −8187.6% | −34238.6% |
| Diluted EPS | $-1.50 | $-1.67 | $-1.49 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 |
| EBITDA | -$175.5M | -$180.2M | -$175.5M | -$164.1M | -$109.2M | -$153.3M | -$136.7M | -$138.4M | -$127.8M | -$123.9M | -$127.4M | -$120.4M |
| Operating cash flow | -$159.8M | -$145.5M | -$142.7M | -$107.5M | -$128.2M | -$131.6M | -$65.6M | -$101.5M | -$99.3M | -$129.5M | -$74.0M | -$96.2M |
| Free cash flow | -$164.2M | -$151.4M | -$148.3M | -$116.9M | -$132.4M | -$137.3M | -$66.9M | -$102.2M | -$101.2M | -$129.5M | -$74.1M | -$96.4M |
| Diluted shares | 132.1M | 123.3M | 122.5M | 120.0M | 119.5M | 118.5M | 119.1M | 117.7M | 109.2M | 101.9M | 99.1M | 96.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $255.3M | $129.8M | $122.5M | $225.5M | $74.9M | $73.7M |
| Short-term investments | $910.4M | $688.7M | $759.7M | $737.1M | $783.2M | $864.5M |
| Total debt | $1.15B | $1.16B | $1.16B | $1.07B | $727.4M | $658.1M |
| Total assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B |
| Total liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B |
| Shareholders' equity | -$173.5M | -$826.6M | -$659.6M | -$521.1M | -$368.7M | -$266.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology